Segment Information (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of segment information - net sales and operating earnings

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.


	Net Sales to External Customers								Operating Earnings
	Three Months Ended June 30				Six Months Ended June 30				Three Months Ended June 30				Six Months Ended June 30
(in millions)	2022		2021		2022		2021		2022		2021		2022		2021
Established Pharmaceutical Products	$	1,223	$	1,180	$	2,370	$	2,250	$	258	$	220	$	500	$	389
Nutritional Products	1,953		2,108		3,847		4,144		230		490		481		957
Diagnostic Products	4,322		3,247		9,608		7,261		1,710		1,076		4,279		2,777
Medical Devices	3,757		3,666		7,322		6,986		1,155		1,208		2,233		2,215
Total Reportable Segments	11,255		10,201		23,147		20,641		3,353		2,994		7,493		6,338
Other	2		22		5		38
Net sales	$	11,257	$	10,223	$	23,152	$	20,679
Corporate functions and benefit plan costs									(123)		(132)		(237)		(246)
Net interest expense									(106)		(123)		(223)		(247)
Share-based compensation (a)									(142)		(132)		(447)		(420)
Amortization of intangible assets									(507)		(504)		(1,019)		(1,013)
Other, net (b)									(123)		(755)		(339)		(1,021)
Earnings before taxes									$	2,352	$	1,348	$	5,228	$	3,391

______________________________________


(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.


(b)			Other, net for the three and six months ended June 30, 2022 includes $42 million and $162 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment. Other, net for the three and six months ended June 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the three and six months ended June 30, 2021 also includes costs related to certain litigation.